Awaiting development: Guidance and quality standards

Showing 21 to 30 of 391

Guidance and quality standards awaiting development
Title	Type
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance
Aprocitentan for treating resistant hypertension [ID6681]	Technology appraisal guidance
Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment	HealthTech guidance
Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care	HealthTech guidance
Artificial intelligence (AI)-derived software to help clinical decision making in stroke	HealthTech guidance
Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [GID-TA12033]	Technology appraisal guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6558]	Technology appraisal guidance